Export as PDF
Cohort Acronym
AIBL

Cohort type
Neurodegenerative disease-specific cohort

Disease
Alzheimer's disease, Mild cognitive impairment (MCI), Other NDs not listed, Subjective memory complaints (SMC) or subjective cognitive decline (SCD)

Participant type
Condition diagnosed

Profile
Recruitment Period 2006-2008| 2010 
Sample size at start or planned sample size if still recruiting 2500  
Estimated Current Sample Size 0 to 4,999 
Age at Recruitment >60   
Gender Male and Female 
Abstract

AIBL is a study of over 2,000 people assessed over a long period of time (over 10 years) to determine which biomarkers, cognitive characteristics, and health and lifestyle factors determine subsequent development of symptomatic Alzheimer’s Disease (AD).

The baseline inception cohort consisted of:
i. 211 individuals with AD as defined by NINCDS-ADRDA (McKhann et al, 1984);
ii. 133 individuals with Mild Cognitive Impairment (MCI)
iii. 768 healthy individuals without cognitive impairment. This group included volunteers with at least one copy of the ApoE ?4 allele, volunteers without a copy of the ApoE ?4 allele and 396 volunteers who expressed subjective concern about their memory function.

The enrichment cohort consists of:
i. 142 individuals with AD
ii. 220 individuals with MCI
iii. 582 individuals with without cognitive impairment.

The data was collected through clinics and questionnaires.

Last Update 21/09/2017

 
Country Australia 
Contact details
Institution name Florey Institute of Neuroscience and Mental Health, Austin Health, Edith Cowan University and CSIRO 
Website https://aibl.csiro.au/about/ 
Principal Investiator (PI) Professor David Ames 
Contact email Email: [email protected] 
Contact phone number  
Address Data Access
https://aibl.csiro.au/research/support/  
Funders (Core support) Science and Industry Endowment Fund 

Variables Collected

Brain related measures: Behaviour, Cognitive function, Mental health, Neurological
Funtional rating: N/A
Anthropometric: Blood pressure, Height, Waist circumference, Weight
Physical: N/A
Biological samples: Blood, Cerebral spinal fluid (CSF), CSF biomarker data available, Microbiome, Other, Saliva, Urine
Genotyping: Gene screening
Brain imaging: Magnetic resonance imaging (MRI), Positron emission tomography (PET) - amyloid
Brain banking: N/A
Lifestyle: Alcohol, Smoking
Socio-economic: Education, Marital status
Health service utilisation: Formal health and social care service utilisation including private care
 
Export as PDF